PERCIVAL DEGRAVA SAMPAIO BARROS
Índice h a partir de 2011
26
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
17 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 17
conferenceObject A CROSS-SECTIONAL EVALUATION OF A BRAZILIAN SPONDYLOARTHRITIS SINGLE-CENTER TERTIARY COHORT: CLINICAL AND TREATMENT DATA(2018) SHIMABUCO, A.; MORAES, J. C. B. de; SAMPAIO-BARROS, P.; GOLDENSTEIN-SCHAINBERG, C.; GONCALVES, C. R.; SAAD, C. G. S.conferenceObject COLLAGEN V/C57BL6 MOUSE MODEL: A NOVEL PRECLINICAL MODEL TO STUDY PATHOPHYSIOLOGY AND THERAPEUTIC APPROACHES IN SYSTEMIC SCLEROSIS(2018) TEODORO, W. R.; VELOSA, A. P. P.; QUEIROZ, Z. A. de J.; SANTOS, L. A. dos; CATANOZI, S.; SANTOS FILHO, A. dos; BUENO, C.; VENDRAMINI, M.; FERNEZLIAN, S. M.; EHER, E. M.; LOPES, F. D. T. Q. S.; SAMPAIO-BARROS, P. D.; CAPELOZZI, V. L.conferenceObject CLINICAL AND LABORATORY PROFILE OF JUVENILE-ONSET SYSTEMIC SCLEROSIS IN A LARGE BRAZILIAN COHORT(2018) SAMPAIO-BARROS, P. D.; BORTOLUZZO, A. B.; RIO, A. P. T. Del; LUPPINO-ASSAD, A. P.; ANDRADE, D. C. O.; MARQUES NETO, J. F.conferenceObject PERIPHERAL NEUROPATHY IN SYSTEMIC SCLEROSIS(2018) TEIXEIRA, J. M. A.; GAVINIER, S.; BORTOLUZZO, A. B.; LUPPINO-ASSAD, A. P.; SILVA, H. C. da; ANDRADE, D. C. O.; SAMPAIO-BARROS, P. D.conferenceObject PREVALENCE AND CHARACTERIZATION OF PSORIATIC ARTHRITIS MUTILANS PATIENTS FROM A SINGLE TERTIARY CENTER(2018) OLIVEIRA, J. L.; CORDEIRO, R. A.; CARRASCO, S.; GONCALVES, C. R.; MORAES, J. C. B.; SAAD, C. G. S.; SAMPAIO-BARROS, P. D.; GOLDENSTEIN-SCHAINBERG, C.conferenceObject ESOPHAGEAL INVOLVEMENT CHARACTERISTICS AND ASSOCIATED FEATURES IN A LARGE COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS(2018) SILVA, H. C. da; BORTOLUZZO, A. B.; LUPPINO-ASSAD, A. P.; ANDRADE, D. C. O.; SAMPAIO-BARROS, P. D.conferenceObject SACROILIITIS IN PATIENTS WITH PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS ARE THERE DIFFERENCES?(2018) LUPPINO-ASSAD, R.; DALTO, V.; OLIVEIRA, R.; NOGUEIRA-BARBOSA, M.; LOUZADA-JUNIOR, P.; SAMPAIO-BARROS, P. D.- Eosinophilic fasciitis during pregnancy: case report and review of literature(2018) FONSECA, Maria Ester Simeira; QUARESMA, Maria Victoria; LUPPINO-ASSAD, Ana Paula; SILVA, Henrique Carrico da; ANDRADE, Danieli Castro O.; SAMPAIO-BARROS, Percival D.The authors describe the case of a 23-year-old woman who was referred to the rheumatologist due to symmetrical and progressive stiffness, induration, and swelling of arms and thighs at the 12th week of her first gestation. The characteristic clinical aspect of 'peau d'orange', associated to the histopathologic results of the deep biopsy of the skin confirmed the diagnosis of eosinophilic fasciitis. Treatment with oral prednisone, at an initial dose of 1 mg/kg/day, was effective and rapidly tapered to 10 mg/day till the birth of a healthy newborn. A literature review showed only one previous description of pregnancy and eosinophilic fasciitis.
- Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors(2018) SHIMABUCO, Andrea Y.; GONCALVES, Celio R.; MORAES, Julio C. B.; WAISBERG, Mariana G.; RIBEIRO, Ana Cristina de M.; SAMPAIO-BARROS, Percival D.; GOLDENSTEIN-SCHAINBERG, Claudia; BONFA, Eloisa; SAAD, Carla G. S.Objective: To determine the clinical and demographic factors associated with disease remission and drug survival in patients with ankylosing spondylitis (AS) on TNF inhibitors. Methods: Data from a longitudinal electronic database of AS patients under anti-TNF therapy between June/2004 and August/2013. Demographic, clinical parameters, disease activity by ASDAS remission (< 1.3) and inactive/low (< 2.1) were analyzed to characterize reasons for drug survival and switching of anti-TNF. Results: Among 117 AS patients, 69 (59%) were prescribed only one anti-TNF, 48 (41%) switched to a second anti-TNF and 13 (11%) to a third anti-TNF. Considering ASDAS-CRP < 1.3, 31 (39%) patients were inactive at the end of the study. Non-switchers (P = 0.04), younger age (P = 0.004), non-smoking (P = 0.016), shorter disease duration (P = 0.047), more frequent use of SSZ (P = 0.037) and lower BASDAI (P = 0.027), BASMI (P = 0.034) and BASFI (P = 0.003) at baseline were associated with remission. In the multivariate analysis younger age (P = 0.016) and lower BASDAI (P = 0.032) remained as remission predictors. Conclusion: This study supports that ASDAS-CRP remission is an achievable goal not only for non-switchers but also for second anti-TNF, particularly in patients with younger age and lower BASDAI at baseline. Co-medication and non-smoker status seems to have a beneficial effect in anti-TNF response in this population.
conferenceObject NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis(2018) LUPPINO-ASSAD, Ana Paula; BORTOLUZZO, Adriana; SILVA, Henrique Carrico da; ANDRADE, Danieli; SAMPAIO-BARROS, Percival